Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 35.27 Million EUR | -18.13% |
| 2022 | 43.08 Million EUR | -18.8% |
| 2021 | 53.06 Million EUR | 14.1% |
| 2020 | 46.5 Million EUR | 23.59% |
| 2019 | 37.62 Million EUR | -40.51% |
| 2018 | 63.25 Million EUR | -18.99% |
| 2017 | 78.07 Million EUR | -37.59% |
| 2016 | 125.1 Million EUR | -3.2% |
| 2015 | 129.23 Million EUR | -14.98% |
| 2014 | 151.99 Million EUR | 756.66% |
| 2013 | 17.74 Million EUR | -19.79% |
| 2012 | 22.12 Million EUR | -35.09% |
| 2011 | 34.08 Million EUR | 29.41% |
| 2010 | 26.33 Million EUR | 23.43% |
| 2009 | 21.33 Million EUR | -49.64% |
| 2008 | 42.36 Million EUR | -33.32% |
| 2007 | 63.53 Million EUR | 179.77% |
| 2006 | 22.71 Million EUR | -31.69% |
| 2005 | 33.24 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 29.34 Million EUR | -16.82% |
| 2024 Q2 | 29.34 Million EUR | 0.0% |
| 2023 Q4 | 35.27 Million EUR | 0.0% |
| 2023 Q3 | 35.27 Million EUR | -19.87% |
| 2023 FY | 35.27 Million EUR | -18.13% |
| 2023 Q2 | 44.02 Million EUR | 0.0% |
| 2023 Q1 | 44.02 Million EUR | 2.17% |
| 2022 Q1 | 56.7 Million EUR | 6.86% |
| 2022 FY | 43.08 Million EUR | -18.8% |
| 2022 Q4 | 43.08 Million EUR | 0.0% |
| 2022 Q3 | 43.08 Million EUR | -24.01% |
| 2022 Q2 | 56.7 Million EUR | 0.0% |
| 2021 FY | 53.06 Million EUR | 14.1% |
| 2021 Q1 | 56.07 Million EUR | 20.57% |
| 2021 Q3 | 53.06 Million EUR | -5.36% |
| 2021 Q4 | 53.06 Million EUR | 0.0% |
| 2021 Q2 | 56.07 Million EUR | 0.0% |
| 2020 Q3 | 46.5 Million EUR | -10.93% |
| 2020 Q2 | 52.21 Million EUR | 0.0% |
| 2020 Q4 | 46.5 Million EUR | 0.0% |
| 2020 FY | 46.5 Million EUR | 23.59% |
| 2020 Q1 | 52.21 Million EUR | 38.76% |
| 2019 Q1 | 58.97 Million EUR | -6.76% |
| 2019 FY | 37.62 Million EUR | -40.51% |
| 2019 Q4 | 37.62 Million EUR | 0.0% |
| 2019 Q3 | 37.62 Million EUR | -36.19% |
| 2019 Q2 | 58.97 Million EUR | 0.0% |
| 2018 Q1 | 58.3 Million EUR | -25.32% |
| 2018 Q2 | 58.3 Million EUR | 0.0% |
| 2018 Q3 | 63.25 Million EUR | 8.49% |
| 2018 Q4 | 63.25 Million EUR | 0.0% |
| 2018 FY | 63.25 Million EUR | -18.99% |
| 2017 Q1 | 125.49 Million EUR | 0.32% |
| 2017 FY | 78.07 Million EUR | -37.59% |
| 2017 Q4 | 78.07 Million EUR | 0.0% |
| 2017 Q3 | 78.07 Million EUR | -37.79% |
| 2017 Q2 | 125.49 Million EUR | 0.0% |
| 2016 FY | 125.1 Million EUR | -3.2% |
| 2016 Q3 | 125.1 Million EUR | 4.45% |
| 2016 Q2 | 119.77 Million EUR | 0.0% |
| 2016 Q1 | 119.77 Million EUR | -7.32% |
| 2016 Q4 | 125.1 Million EUR | 0.0% |
| 2015 Q2 | 138.02 Million EUR | 0.0% |
| 2015 Q4 | 129.23 Million EUR | 0.0% |
| 2015 FY | 129.23 Million EUR | -14.98% |
| 2015 Q1 | 138.02 Million EUR | -9.2% |
| 2015 Q3 | 129.23 Million EUR | -6.37% |
| 2014 Q3 | 151.99 Million EUR | 53.53% |
| 2014 Q4 | 151.99 Million EUR | -0.0% |
| 2014 Q2 | 99 Million EUR | 0.0% |
| 2014 FY | 151.99 Million EUR | 756.66% |
| 2014 Q1 | 99 Million EUR | 457.99% |
| 2013 Q4 | 17.74 Million EUR | 0.06% |
| 2013 FY | 17.74 Million EUR | -19.79% |
| 2013 Q3 | 17.73 Million EUR | 4.39% |
| 2013 Q2 | 16.98 Million EUR | 0.0% |
| 2013 Q1 | 16.98 Million EUR | -23.21% |
| 2012 FY | 22.12 Million EUR | -35.09% |
| 2012 Q2 | 24.85 Million EUR | 0.0% |
| 2012 Q4 | 22.12 Million EUR | 0.0% |
| 2011 Q4 | 34.08 Million EUR | 0.0% |
| 2011 FY | 34.08 Million EUR | 29.41% |
| 2011 Q2 | 20.94 Million EUR | 0.0% |
| 2010 FY | 26.33 Million EUR | 23.43% |
| 2010 Q4 | 26.33 Million EUR | 0.0% |
| 2010 Q2 | 34.39 Million EUR | 0.0% |
| 2009 Q4 | 21.33 Million EUR | 0.0% |
| 2009 FY | 21.33 Million EUR | -49.64% |
| 2008 FY | 42.36 Million EUR | -33.32% |
| 2007 FY | 63.53 Million EUR | 179.77% |
| 2006 FY | 22.71 Million EUR | -31.69% |
| 2005 FY | 33.24 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -139.796% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 89.215% |
| Adocia SA | 24.95 Million EUR | -41.345% |
| Aelis Farma SA | 26.28 Million EUR | -34.219% |
| Biophytis S.A. | 11.93 Million EUR | -195.526% |
| Advicenne S.A. | 12.4 Million EUR | -184.307% |
| genOway Société anonyme | 31.84 Million EUR | -10.777% |
| IntegraGen SA | 8 Million EUR | -340.906% |
| Medesis Pharma S.A. | 1.92 Million EUR | -1731.146% |
| Neovacs S.A. | 47.53 Million EUR | 25.791% |
| NFL Biosciences SA | 3.97 Million EUR | -788.373% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -136.533% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -841.451% |
| Sensorion SA | 46.49 Million EUR | 24.132% |
| Theranexus Société Anonyme | 7.23 Million EUR | -387.362% |
| TME Pharma N.V. | 2.49 Million EUR | -1316.058% |
| Valbiotis SA | 33.24 Million EUR | -6.094% |
| TheraVet SA | 7.53 Million EUR | -368.186% |
| argenx SE | 4.11 Billion EUR | 99.142% |
| BioSenic S.A. | 9.55 Million EUR | -269.013% |
| Celyad Oncology SA | 16.28 Million EUR | -116.644% |
| DBV Technologies S.A. | 165.65 Million USD | 78.706% |
| Galapagos NV | 4.35 Billion EUR | 99.19% |
| Genfit S.A. | 173.87 Million EUR | 79.713% |
| GeNeuro SA | 6.31 Million EUR | -458.761% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 26.021% |
| Innate Pharma S.A. | 184.19 Million EUR | 80.849% |
| Inventiva S.A. | 69.13 Million EUR | 48.981% |
| MaaT Pharma SA | 42.93 Million EUR | 17.836% |
| MedinCell S.A. | 36.94 Million EUR | 4.531% |
| Nanobiotix S.A. | 93.89 Million EUR | 62.433% |
| Onward Medical N.V. | 43.62 Million EUR | 19.15% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 67.003% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 56.93% |
| Oxurion NV | 6.55 Million EUR | -438.534% |
| Pharming Group N.V. | 426.33 Million EUR | 91.726% |
| Poxel S.A. | 4.82 Million EUR | -631.371% |
| GenSight Biologics S.A. | 9.08 Million EUR | -288.181% |
| Transgene SA | 45.21 Million EUR | 21.99% |
| Financière de Tubize SA | 1.92 Billion EUR | 98.163% |
| UCB SA | 15.53 Billion EUR | 99.773% |
| Valneva SE | 469.39 Million EUR | 92.485% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -14.418% |